News &amp; Updates

Once-weekly treatment with tirzepatide at either 10 or 15 mg appears to yield substantial reductions in weight, according to data from the phase III SURMOUNT-CN trial.

Weekly tirzepatide works for weight loss in Chinese adults with obesity

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

20 Jun 2024 by

In patients with HRS accompanied by rapidly progressive worsening in kidney function, an interruption of terlipressin dose does not appear to hinder the achievement of HRS reversal, according to a post hoc analysis of data from the CONFIRM study presented at DDW 2024

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

20 Jun 2024 by

Treatment with bulevirtide, either 2 or 10 mg, has shown sustained improvement in virologic and biochemical responses in patients with chronic hepatitis delta (CHD), according to the MYR301 study presented at EASL 2024.

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

Heat exposure ups myocardial blood flow in adults

Myocardial blood flow (MBF) tends to double in heat-exposed individuals who show an increase of 1.5°C in core temperature, reveals a study.

Heat exposure ups myocardial blood flow in adults

Statin use may reduce mortality in early breast cancer

The addition of statins to standard adjuvant breast cancer treatment, particularly in combination with chemotherapy, appears to improve patient survival, suggests a study presented at ESMO Breast Cancer 2024.

Statin use may reduce mortality in early breast cancer

19 Jun 2024

Blunted nocturnal BP decline predicts all-cause, cardiovascular mortality

Aberrations in the circadian pattern appear to elevate the risk of all-cause and cardiovascular mortality, even without elevations in nocturnal blood pressure (BP), reveals a study.

Blunted nocturnal BP decline predicts all-cause, cardiovascular mortality

Physical activity substantially cuts cirrhosis risk in MASLD patients

A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

Physical activity substantially cuts cirrhosis risk in MASLD patients

19 Jun 2024

Achieving low-risk status in PAH with prostacyclin receptor agonist–based triple therapy

A 72-year-old female with a history of well-controlled hypertension presented with unexplained dyspnoea and reduced exercise tolerance for the past 2–3 years.

Achieving low-risk status in PAH with prostacyclin receptor agonist–based triple therapy

Early diagnosis and management of AL amyloidosis: An underdiagnosed multiorgan disease

Light-chain (AL) amyloidosis is a progressive, underdiagnosed disease with multiorgan involvement, most notably of the heart, kidneys, and liver. Nearly half of the patients consult ≥4 physicians before receiving correct diagnosis. At the Hong Kong Society of Haematology Annual Scientific Meeting (HKSH ASM) 2024, Professor Morie Gertz of the Mayo Clinic, Minnesota, US, shared insights into establishing an early and accurate diagnosis and discussed the ANDROMEDA trial, which led to the first US FDA–approved treatment – daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd).

Early diagnosis and management of AL amyloidosis: An underdiagnosed multiorgan disease

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

Long-term treatment with elafibranor improves biochemical response and itch-related quality of life (QoL) in patients with primary biliary cholangitis (PBC), according to data from the ELATIVE trial presented at EASL 2024.

Elafibranor improves biochemical response, itch-related QoL in patients with PBC